Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 8/2016

01-08-2016 | Review Article

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Authors: Vincent Madelain, Thi Huyen Tram Nguyen, Anaelle Olivo, Xavier de Lamballerie, Jérémie Guedj, Anne-Marie Taburet, France Mentré

Published in: Clinical Pharmacokinetics | Issue 8/2016

Login to get access

Abstract

The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had proven antiviral efficacy in patients. However, in September 2014, the World Health Organization inventoried and has since regularly updated a list of potential drug candidates with demonstrated antiviral efficacy in in vitro or animal models. This includes agents belonging to various therapeutic classes, namely direct antiviral agents (favipiravir and BCX4430), a combination of antibodies (ZMapp), type I interferons, RNA interference-based drugs (TKM-Ebola and AVI-7537), and anticoagulant drugs (rNAPc2). Here, we review the pharmacokinetic and pharmacodynamic information presently available for these drugs, using data obtained in healthy volunteers for pharmacokinetics and data obtained in human clinical trials or animal models for pharmacodynamics. Future studies evaluating these drugs in clinical trials are critical to confirm their efficacy in humans, propose appropriate doses, and evaluate the possibility of treatment combinations.
Literature
1.
Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271–93.PubMedCentral
2.
3.
4.
Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, Leroy EM, et al. Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol. 2014;159:821–30.CrossRefPubMedPubMedCentral
5.
Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155:2083–103.CrossRefPubMedPubMedCentral
6.
7.
Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs Clin Immunother Biopharm Gene Ther. 2013;27:565–83.
8.
9.
10.
Moyen N, Thirion L, Emmerich P, Dzia-Lepfoundzou A, Richet H, Boehmann Y, et al. Risk factors associated with Ebola and Marburg viruses seroprevalence in blood donors in the Republic of Congo. PLoS Negl Trop Dis. 2015;9:e0003833.CrossRefPubMedPubMedCentral
11.
Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet Lond Engl. 2000;355:2210–5.CrossRef
12.
Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–100.CrossRefPubMedPubMedCentral
13.
Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease. Intensive Care Med. 2015;41:115–7.CrossRefPubMed
14.
Fowler RA, Fletcher T, Fischer WA, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with Ebola virus disease: perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733–7.CrossRefPubMed
15.
van Griensven J, De Weiggheleire A, Delamou A, Smith PG, Edwards T, Vandekerckhove P, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2016;62(1):69–74.
16.
17.
18.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013;100:446–54.CrossRefPubMed
19.
20.
Toyama Chemicals. Summary of product characteristics of Avigan (unpublished reference).
21.
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res. 2014;105:17–21.CrossRefPubMed
22.
Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir Res. 2014;104:153–5.CrossRefPubMed
23.
Madelain V, Oestereich L, Graw F, Nguyen THT, de Lamballerie X, Mentré F, et al. Ebola virus dynamics in mice treated with favipiravir. Antivir Res. 2015;123:70–7.CrossRefPubMed
24.
Sissoko D, Laouenan C, Folkessons E, M’Lebing AB, Beavogui AH, Baize S et al. Favipiravir for treatment of Ebola virus disease (the JIKI Trial): a historically-controlled, single arm proof-of-concept trial in Guinea. PLOS Medicine. 2016. (In press)
25.
Mentré F, Taburet A-M, Guedj J, Anglaret X, Keïta S, de Lamballerie X, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015;15:150–1.CrossRefPubMed
26.
Bouazza N, Treluyer J-M, Foissac F, Mentré F, Taburet A-M, Guedj J, et al. Favipiravir for children with Ebola. Lancet. 2015;385:603–4.CrossRefPubMed
27.
Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508:402–5.CrossRefPubMed
28.
Stonehouse J, Staab T, Bennett R. 26th Annual Piper Jaffray Healthcare Conference. New York, USA; 2014.
29.
Stonehouse J, Sheridan B, Staab T, Bennett R. Citi 10th Annual Biotech Conference. Boston, USA; 2015.
30.
31.
Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53.PubMedPubMedCentral
32.
Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci. 2014;111:17182–7.CrossRefPubMedPubMedCentral
33.
Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci. 2011;108:20690–4.CrossRefPubMedPubMedCentral
34.
35.
36.
Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, et al. Therapeutic intervention of ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5:199ra113.CrossRefPubMed
37.
Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci. 2012;109:18030–5.CrossRefPubMedPubMedCentral
38.
Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013;3:3365.PubMedPubMedCentral
39.
Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, et al. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med. 2013;5:207ra143.CrossRefPubMed
40.
41.
George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135:44–53.CrossRefPubMed
42.
Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons alpha, beta and omega. Growth Factors. 2004;22:243–51.CrossRefPubMed
43.
44.
45.
Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol. 2014;10:781–90.CrossRefPubMed
46.
Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80:171–86.CrossRefPubMed
47.
Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34–55.CrossRefPubMed
48.
Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, et al. Pharmacokinetics of Interferon α-2b in Healthy Volunteers. J Clin Pharmacol. 1987;27:432–5.CrossRefPubMed
49.
50.
Rogge MC, Liu Y, Galluppi GR. Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent. J Clin Pharmacol. 2014;54:1153–61.CrossRefPubMed
51.
Subramanian GM, Moore PA, Gowen BB, Olsen AL, Barnard DL, Paragas J, et al. Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy. 2008;54:176–80.CrossRefPubMed
52.
Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis. 1999;179(Suppl 1):S224–34.CrossRefPubMed
53.
Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, et al. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2013;208:310–8.CrossRefPubMed
54.
Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4:138ra81–138ra81.CrossRef
55.
Thi EP, Mire CE, Lee ACH, Geisbert JB, Zhou JZ, Agans KN, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 2015;521:362–5.CrossRefPubMedPubMedCentral
56.
57.
58.
Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61:496–502.CrossRefPubMed
59.
Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896–905.CrossRefPubMed
60.
61.
Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother. 2014;58:6639–47.CrossRefPubMedPubMedCentral
62.
Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses. 2012;4:2806–30.CrossRefPubMedPubMedCentral
63.
Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16:991–4.CrossRefPubMed
64.
Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, Charleston JS, et al. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal ebola virus infection. mBio. 2015;6:e02344–14.CrossRefPubMedPubMedCentral
65.
Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci. 1996;93:2149–54.CrossRefPubMedPubMedCentral
66.
Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188:1618–29.CrossRefPubMed
67.
de Pont ACJM, Moons AHM, de Jonge E, Meijers JCM, Vlasuk GP, Rote WE, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost. 2004;2:65–70.CrossRefPubMed
68.
Vlasuk GP, Bradbury A, Lopez-Kinninger L, Colón S, Bergum PW, Maki S, et al. Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode anticoagulant protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X. Thromb Haemost. 2003;90:803–12.PubMed
69.
Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007;49:2398–407.CrossRefPubMed
70.
Lee A, Agnelli G, Büller H, Ginsberg J, Heit J, Rote W, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001;104:74–8.CrossRefPubMed
71.
Moons AHM, Bijsterveld NR, Koch KT, Meijers JCM, Tijssen JGP, van der Poll T, et al. Inhibition of the tissue factor pathway of coagulation by recombinant nematode anticoagulant protein c2 during elective coronary stent implantation. Neth Heart J. 2004;12:48–54.PubMedPubMedCentral
72.
Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953–8.CrossRefPubMed
73.
Hites M, Dell’Anna AM, Scolletta S, Taccone FS. The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev. 2014;77:12–21.CrossRefPubMed
74.
Roberts DJ, Hall RI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013;9:1067–84.PubMed
75.
Shurtleff AC, Warren TK, Bavari S. Nonhuman primates as models for the discovery and development of ebolavirus therapeutics. Expert Opin Drug Discov. 2011;6:233–50.CrossRefPubMed
76.
77.
78.
79.
Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One. 2013;8:e56265.CrossRefPubMedPubMedCentral
80.
Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69:2123–31.CrossRefPubMed
81.
Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog. 2012;8:e1002845.CrossRefPubMedPubMedCentral
82.
Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, et al. Identification of a small-molecule entry inhibitor for filoviruses. J Virol. 2011;85:3106–19.CrossRefPubMedPubMedCentral
83.
Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci. 2010;107:3157–62.CrossRefPubMedPubMedCentral
84.
Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature. 2011;477:344–8.CrossRefPubMedPubMedCentral
85.
Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother. 2010;54:2152–9.CrossRefPubMedPubMedCentral
86.
Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res. 2009;1:87–98.PubMedPubMedCentral
87.
Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antivir Res. 2009;83:245–51.CrossRefPubMed
88.
Nguyen T, Guedj J. HCV kinetic models and their implications in drug development. CPT Pharmacomet Syst Pharmacol. 2015;4:231–42.CrossRef
89.
90.
Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196:S142–7.CrossRefPubMed
91.
Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med. 2015;372:2423–7.CrossRefPubMedPubMedCentral
92.
Tully CM, Lambe T, Gilbert SC, Hill AVS. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infect Dis. 2015;15:356–9.CrossRefPubMed
93.
Martínez MJ, Salim AM, Hurtado JC, Kilgore PE. Ebola virus infection: overview and update on prevention and treatment. Infect Dis Ther. 2015;4(4):365–90.CrossRefPubMedPubMedCentral
94.
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–66.CrossRefPubMed
Metadata
Title
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials
Authors
Vincent Madelain
Thi Huyen Tram Nguyen
Anaelle Olivo
Xavier de Lamballerie
Jérémie Guedj
Anne-Marie Taburet
France Mentré
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2016
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0364-1

Other articles of this Issue 8/2016

Clinical Pharmacokinetics 8/2016 Go to the issue

Original Research Article

Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias

Original Research Article

Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy

Original Research Article

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

Current Opinion

Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools

Original Research Article

A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults

Original Research Article

Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers